Valuation
- Market cap
- 443,176,000
- Revenue TTM
- $0
- Net income TTM
- $-74,150,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 253,400
- Avg volume
- 226,766
- Day's range
- $22.14 – $23.07
- Shares out
- 19,549,000
- Stochastic %K
- 7%
- Beta
- 3.29
- Analysts
- Strong Sell
- Price target
- $76.62
Company profile
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPC...
Show more
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 339 666 3320
- Website
- https://tectonictx.com
- Address
- 490 Arsenal Way, Suite 210, Watertown, United States
Latest news
No headlines yet.
